Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Curigliano, G
Dent, R
Llombart-Cussac, A
Pegram, M
Pusztai, L
Turner, N
Viale, G
Dent, R
Llombart-Cussac, A
Pegram, M
Pusztai, L
Turner, N
Viale, G
Document Type
Journal Article
Date
2023-06-28
Date Accepted
2023-06-06
Abstract
Stratification of recurrence risk is a cornerstone of early breast cancer diagnosis that informs a patient's optimal treatment pathway. Several tools exist that combine clinicopathological and molecular information, including multigene assays, which can estimate risk of recurrence and quantify the potential benefit of different adjuvant treatment modalities. While the tools endorsed by treatment guidelines are supported by level I and II evidence and provide similar prognostic accuracy at the population level, they can yield discordant risk prediction at the individual patient level. This review examines the evidence for these tools in clinical practice and offers a perspective of potential future risk stratification strategies. Experience from clinical trials with cyclin D kinase 4/6 (CDK4/6) inhibitors in the setting of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is provided as an illustrative example of risk stratification.
Citation
npj Breast Cancer, 2023, 9 (1), pp. 56 -
Source Title
npj Breast Cancer
Publisher
NATURE PORTFOLIO
ISSN
2374-4677
eISSN
2374-4677
2374-4677
2374-4677
Collections
Research Team
Molecular Oncology